Powerful HIV antibodies and therapeutic vaccines to delay the virus coming back
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
This project looks at whether special HIV-fighting antibodies and therapeutic vaccines can help people with HIV keep the virus from returning after stopping ART.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11330320 on NIH RePORTER |
What this research studies
You would be helping researchers learn how broadly neutralizing antibodies (bNAbs) and therapeutic vaccines act by providing blood or tissue samples from previous human studies and linking your results to detailed lab work. The team will also run new experiments in nonhuman primates to test ideas about how these approaches target the viral reservoir. They will use high-throughput "multi-omic" techniques to map virus and immune cells across tissues like lymph nodes and the gut. Those combined data aim to reveal what immune and tissue features delay viral rebound so future treatments can be improved.
Who could benefit from this research
Good fit: Ideal candidates are people living with HIV who have been on antiretroviral therapy and who have participated in or might consider interventions involving bNAbs, therapeutic vaccines, or planned analytic treatment interruption.
Not a fit: People who do not have HIV or who are not candidates for ART interruption, bNAb, or vaccine studies would not directly benefit from this project.
Why it matters
Potential benefit: If successful, this work could lead to antibody- or vaccine-based approaches that delay or prevent HIV from returning after stopping ART, reducing the need for continuous therapy.
How similar studies have performed: Previous human and nonhuman primate studies have sometimes shown that bNAbs and therapeutic vaccines can delay viral rebound, but durable cures have not yet been achieved so this approach is promising but not proven.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Barouch, Dan H. — Beth Israel Deaconess Medical Center
- Study coordinator: Barouch, Dan H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.